AstraZeneca PLC (AZNCF) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Cambridge, United Kingdom. The current CEO is Pascal Claude Roland Soriot.
AZNCF has IPO date of 2009-02-13, 94,300 full-time employees, listed on the Other OTC, a market capitalization of $294.4B.
AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom, specializing in the discovery, development, manufacturing, and commercialization of prescription medicines. The company maintains a diverse portfolio spanning oncology, cardiovascular and metabolic diseases, respiratory and immunology, and rare diseases, with marketed products including Tagrisso, Lynparza, and Imfinzi for cancer; Farxiga and Crestor for heart and metabolic conditions; Symbicort and Fasenra for respiratory care; and Soliris for rare diseases, among many others. AstraZeneca also markets vaccines and treatments for respiratory syncytial virus, influenza, COVID-19, and other therapeutic areas. The company distributes its medicines through a global network of physicians and representatives across Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca maintains strategic collaborations with leading pharmaceutical and biotechnology partners, including Regeneron Pharmaceuticals for obesity treatments and Ionis Pharmaceuticals for antisense therapies in development.
